Current Oncology Reports

, Volume 4, Issue 3, pp 193–201

Recent developments in the treatment of gastric carcinoma

  • Manish A. Shah


Surgery remains the mainstay for the curative treatment of gastric carcinoma. However, despite adequate surgery, survival remains poor. The use of adjuvant chemotherapy and radiotherapy has been examined in multiple previous clinical trials without convincing evidence of efficacy. However, recently, a large randomized controlled Intergroup trial, INT 116, demonstrated a survival advantage with chemoradiotherapy following curative surgery for gastric cancer. This review discusses the merits of the Intergroup trial and the ways in which it should affect the treatment of gastric cancer in the United States. INT 116 provides a foundation on which we can build to improve the care of patients with gastric cancer. With the evaluation of potentially better chemotherapeutic agents and the advent of molecularly directed therapy, there is increasing hope for improving the care of patients with gastric carcinoma.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics, 2001. CA Cancer J Clin 2001, 51:15–36.PubMedGoogle Scholar
  2. 2.
    Correa P: The epidemiology of gastric cancer. World J Surg 1991, 15:228–234.PubMedCrossRefGoogle Scholar
  3. 3.
    Franceschi S, Levi F, La Vecchia C: Epidemiology of gastric cancer in Europe. Eur J Cancer Prev 1994, 3:5–10.PubMedCrossRefGoogle Scholar
  4. 4.
    Dupont J, Lee J, Burton G, Cohn I: Adenocarcinoma of the stomach: review of 1,497 cases. Cancer 1978, 41:941–947.PubMedCrossRefGoogle Scholar
  5. 5.
    Kelsen DP: Postoperative adjuvant chemoradiation therapy for patients with resected gastric cancer: Intergroup 116. J Clin Oncol 2000, 18:32s-34s.PubMedGoogle Scholar
  6. 6.
    MacDonald J, Smalley S, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725–730. This article reports the results of INT 116, a benchmark study that demonstrates a survival advantage for chemoradiotherapy following R0 resection of gastric carcinoma.PubMedCrossRefGoogle Scholar
  7. 7.
    Siewert JR, Bottcher K, Roder JD, et al.: Prognostic relevance of systemic lymph node dissection in gastric carcinoma. Br J Surg 1993, 80:1015–1018.PubMedCrossRefGoogle Scholar
  8. 8.
    Hundahl S, Phillips J, Menck H: The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth edition American Joint Committee on Cancer staging, proximal disease, and the ‘different disease’ hypothesis. Cancer 2000, 88:921–932. An excellent review describing gastric carcinoma in the United States and comparing it with the disease in Japan. The authors explain the reasons why survival following resection is different in the two countries, and they argue for improving the surgical resection of this disease in the United States.PubMedCrossRefGoogle Scholar
  9. 9.
    Bonenkamp J, Herman S, Sasaki M, et al.: Extended lymph-node dissection for gastric cancer. N Engl J Med 1999, 340:908–914. This article describes a prospective randomized controlled trial comparing extended lymphadenectomy (D2 dissection) with the more standard D1 dissection.PubMedCrossRefGoogle Scholar
  10. 10.
    Cuschieri A, Weeden S, Fielding J, et al.: Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Cooperative Group. Br J Cancer 1999, 79:1522–1530.PubMedCrossRefGoogle Scholar
  11. 11.
    Roder J, Bottcher K, Busch R, et al.: Classification of regional lymph node metastasis from gastric carcinoma. Cancer 1998, 82:621–631.PubMedCrossRefGoogle Scholar
  12. 12.
    Hundahl S, Menck H, Mansour E, Winchester D: The National Cancer Data Base report on gastric carcinoma. Cancer 1997, 80:2333–2341.PubMedCrossRefGoogle Scholar
  13. 13.
    Janunger KG, Hafstrom L, Nygren P, Glimelius B: A systemic overview of chemotherapy effects in gastric cancer. Acta Oncol 2001, 40:309–326. An excellent review of the role of chemotherapy in the treatment of gastric cancer. It includes a meta-analysis of the adjuvant trials in this disease.PubMedCrossRefGoogle Scholar
  14. 14.
    Nakajima T, Takahashi T, Takagi K, et al.: Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol 1984, 2:1366–1371.PubMedGoogle Scholar
  15. 15.
    Shimada K, Ajani J: Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of Western and Oriental trials. Cancer 1999, 86:1657–1668.PubMedCrossRefGoogle Scholar
  16. 16.
    Sasako M, Sano T, Katai H, et al.: Overview of clinical trials on adjuvant chemotherapy for curatively resected gastric cancer. Gan To Kagaku Ryoho 1994, 21:384–394.PubMedGoogle Scholar
  17. 17.
    Noguchi Y, Yoshikawa T, Tsuburaya A, et al.: Is gastric cancer different between Japan and the United States? A comparison of patient survival among three institutions. Cancer 2000, 89:2237–2246.PubMedCrossRefGoogle Scholar
  18. 18.
    Webb A, Cunningham D, Scarffe JH, et al.: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997, 15:261–267.PubMedGoogle Scholar
  19. 19.
    Gunderson L, Sosin H: Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look), clinicopatholgic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982, 8:1–11.PubMedGoogle Scholar
  20. 20.
    Allum W, Hallissey M, Ward L, Hockey M: A controlled, prospective, randomized trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. Br J Cancer 1989, 60:739–744.PubMedGoogle Scholar
  21. 21.
    Laundry J, Tepper J, Wood W, et al.: Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys 1990, 19:1357–1362.Google Scholar
  22. 22.
    Hallissey M, Dunn J, Ward L, Allum W: The second British Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 1994, 343:1309–1312.PubMedCrossRefGoogle Scholar
  23. 23.
    Group GTS: The concept of locally advanced gastric cancer: effect of treatment on outcome. Cancer 1990, 49:1771–1777.Google Scholar
  24. 24.
    Moertel C, Childs D, O’Fallon J, et al.: Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol 1984, 2:1249–1254.PubMedGoogle Scholar
  25. 25.
    Moertel C, Childs D, Reitemeier R, et al.: Combined 5-fluorouracil plus supervoltage radiation therapy of locally unresectable gastrointestinal carcinoma. Lancet 1969, 1:865–870.CrossRefGoogle Scholar
  26. 26.
    Schein P, Smith F, Wolley P, et al.: Current management of advanced and locally unresectable gastric carcinoma. Cancer 1982, 66:2590–2596.Google Scholar
  27. 27.
    Wanebo H, Kennedy BJ, Chmiel J, et al.: Cancer of the stomach: a patient care study by the American College of Surgeons. Ann Surg 1993, 218:583–592.PubMedCrossRefGoogle Scholar
  28. 28.
    Kapiteijn E, Marijnen C, Nagtegaal I, et al.: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001, 345:638–646.PubMedCrossRefGoogle Scholar
  29. 29.
    Glimelius B, Ekstrom K, Hoffman K, et al.: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997, 8:163–168.PubMedCrossRefGoogle Scholar
  30. 30.
    Murad A, Santiago F, Petroianu A, et al.: Modified therapy with 5-fluorouracil, doxorubiin, and methotrexate in advanced gastric cancer. Cancer 1993, 72:37–41.PubMedCrossRefGoogle Scholar
  31. 31.
    Pyrhonen S, Kuitenen T, Nyandoto P, et al.: Randomised comparison of fluorouracil, epidoxorubicin, and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995, 71:587–591.PubMedGoogle Scholar
  32. 32.
    Scheithauer W, Kornek G, Zeh B, et al.: Palliative chemotherapy vs. supportive care in patients with metastatic gastric cancer: a randomized trial. In Proceedings of the Second International Conference on Biology, Prevention and Treatment of GI Malignancy. Koln, Germany; 1995:68.Google Scholar
  33. 33.
    Vanhoefer U, Rougier P, Wilke H, et al.: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin verses etoposide, leucovorin, and cisplatin in advanced gastric cancer: an EORTC trial. J Clin Oncol 2000, 18:2648–2657. This article describes the recent randomized controlled trial of three different chemotherapy combinations in the treatment of gastric cancer. It makes the point that the 5-FU-based treatment arms were all equivalently poor, and that better therapy is desperately needed.PubMedGoogle Scholar
  34. 34.
    Sulkes A, Smyth J, Sessa C, et al.: Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 1994, 70:380–383.PubMedGoogle Scholar
  35. 35.
    Mavroudis D, Kourousis C, Androulakis N, et al.: Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. Am J Clin Oncol 2000, 23:341–344.PubMedCrossRefGoogle Scholar
  36. 36.
    Yamada Y, Shirao K, Ohtsu A, et al.: Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 2001, 12:1133–1137.PubMedCrossRefGoogle Scholar
  37. 37.
    Garcia A, Leichman C, Lenz H, et al.: Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomach. Jpn J Clin Oncol 2001, 31:275–278.PubMedCrossRefGoogle Scholar
  38. 38.
    Graziano F, Catalano V, Baldelli A, et al.: A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 2000, 11:1263–1266.PubMedCrossRefGoogle Scholar
  39. 39.
    Kohne CH, Thuss-Patience P, Catone R, et al.: Final results of a phase II trial of CPT-11 in patients with advanced gastric cancer [abstract]. Proc ASCO 1999, 18:993a.Google Scholar
  40. 40.
    Lin L-S, Hecht JR: A phase II trial of irinotecan in patients with advanced adenocarcinoma of the gastroesophageal (GE) junction [abstract]. Proc ASCO 2000, 19:1130a.Google Scholar
  41. 41.
    Futatsuki K, Wakui A, Nakao I, et al.: Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho 1994, 7:1033–1038.Google Scholar
  42. 42.
    Einzig A, Neuberg D, Remick S, et al.: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Group (ECOG) results of protocol E1293. Med Oncol 1996, 13:87–93.PubMedCrossRefGoogle Scholar
  43. 43.
    Pozzo C, Bugat R, Peschel C, et al.: Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma: final results of a randomized phase II study [abstract]. Proc ASCO 2001, 21:531a.Google Scholar
  44. 44.
    Ridwelski K, Gebauer T, Fahlke J, Kroning H, et al.: Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001, 12:47–51.PubMedCrossRefGoogle Scholar
  45. 45.
    Roth A, Maibach R, Martinelli G, et al.: Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology. Ann Oncol 2000, 11:301–306.PubMedCrossRefGoogle Scholar
  46. 46.
    Kim JS, Shin SW, Kim HS, et al.: A phase II trial of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced gastric carcinoma [abstract]. Proc ASCO 1997, 16:293a.Google Scholar
  47. 47.
    Kollmannsberger C, Quietzsch D, Haag C, et al.: A phase II study of paclitaxel, weekly 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2000, 83:458–462.PubMedCrossRefGoogle Scholar
  48. 48.
    Boku N, Ohtsu A, Shimada Y, et al.: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999, 17:319–323.PubMedGoogle Scholar
  49. 49.
    Ajani J, Baker J, Pisters P, Feig, et al.: Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology 2001, 15:52–54.PubMedGoogle Scholar
  50. 50.
    Van Custem E, Ajani J, Tjulandin S, et al.: Docetaxel (T) in combination with cisplatinum (C) with or without 5-fluorouracil (F) in patients (pts) with advanced gastric or GE junction adenocarcinoma (AGC): preliminary results. Ann Oncol 2000, 11:63a.Google Scholar
  51. 51.
    Van Oosteram AT, Judson I, Verweij J, et al.: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet 2001, 358:1421–1423. This is the first report of the use of imatinib in gastrointestinal stromal tumors. The authors report on the remarkable success of this drug in a phase I clinical trial setting.CrossRefGoogle Scholar
  52. 52.
    Druker B, Sawyers C, Kantarjian H, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038–1042.PubMedCrossRefGoogle Scholar
  53. 53.
    Buchdunger E, Cioffi CL, Law N, et al.: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharm Exp Ther 2000, 295:139–145.Google Scholar
  54. 54.
    Plaat B, Hollema H, Molenaar W, et al.: Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000, 18:3211–3220.PubMedGoogle Scholar
  55. 55.
    Shah MA, Schwartz GK: Cell cycle mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 2001, 7:2168–2181. This is an overview of a novel concept of cell cycle-mediated drug resistance in cancer chemotherapy. The authors describe the cell cycle and the effects of standard cytotoxic drugs on this cycle.PubMedGoogle Scholar
  56. 56.
    Schwartz GK, Ilson D, Saltz L, et al.: Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001, 19:1985–1992.PubMedGoogle Scholar
  57. 57.
    Stadler WM, Vogelzang NJ, Amato R, et al.: Flavopiridol, a novel cyclin dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol 2000, 18:371–375.PubMedGoogle Scholar
  58. 58.
    Motwani M, Jung C, Sirotnak FM, et al.: Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in HCT-116 colon cancer monolayers and xenografts. Clin Cancer Res 2001, 7:4209–4219.PubMedGoogle Scholar
  59. 59.
    Motwani M, Delohery TM, Schwartz GK: Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 1999, 5:1876–1883.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Manish A. Shah
    • 1
  1. 1.Gastrointestinal Oncology ServiceDepartment of Medicine, Memorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations